The Latest Breaking News from PTC Therapeutics

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

PTC stock opened at a nine-month high Monday after the EC decided against pulling its drug, Translarna, from the market.

PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

PTC stock rose Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy.

European regulators voted against fully approving a muscular dystrophy treatment from PTC Therapeutics, and PTC stock crashed Friday.

The stock market retreated Tuesday, with many leaders slammed as debt-ceiling talks continue. Nvidia earnings loom large.

PTC stock plummeted Wednesday and gave its closest rival a boost after the company's treatment for a neurological disorder flunked.

The Chart of the Day belongs to the biopharmaceutical company PTC Therapeutics (PTCT) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...